IBRANCE® is indicated for the treatment of HR+/HER2- locally advanced or mBC in combination with an AI or with fulvestrant in patients who have received prior ET. In pre- or peri-menopausal women, the ET should be combined with an LHRH agonist.1
Summary of Product Characteristics
Summary of Product Characteristics
Reference
- IBRANCE® Summary of Product Characteristics.
PP-IBR-IRL-0288
Date of preparation: March 2020
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
Summary of Product Characteristics
